Anthony Hunt - Repligen President CEO, Director

RGEN
 Stock
  

USD 173.87  3.54  2.08%   

  CEO
Mr. Anthony John Hunt is President, Chief Executive Officer, Director of the Company. He is no longer Chief Operating Officer, Treasurer of the Company until May 21, 2015. Mr. Hunt joined Life Technologies in 2008, first as General Manager, BioProduction Chromatography and Pharma Analytics before being named President, BioProduction in 2011. In this most recent role, where he led an organization of approximately 200 employees, his responsibilities included commercial operations and research and development, as well as product management and marketing. Prior to this role, Mr. Hunt was with Applied Biosystems for eight years, most recently as Senior Director, Pharma Programs where he launched the pharma analytics business that in 2008 became a part of the bioproduction platform at Life Technologies
Age: 58  CEO Since 2015      
781 250 0111  https://www.repligen.com
Hunt began his career with Repligen where he was involved in process development. He received a Bachelors of Science degree in microbiology from University College Galway, Ireland, a Masters of Science degree in biotechnology from University College Galway, Ireland, and a Masters of Business Administration from Boston University School of Management.

Anthony Hunt Latest Insider Activity

Tracking and analyzing the buying and selling activities of Anthony Hunt against Repligen stock is an integral part of due diligence when investing in Repligen. Anthony Hunt insider activity provides valuable insight into whether Repligen is net buyers or sellers over its current business cycle. Note, Repligen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Repligen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Repligen Management Efficiency

Repligen has return on total asset (ROA) of 0.0573 % which means that it generated profit of $0.0573 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.0937 %, meaning that it created $0.0937 on every $100 dollars invested by stockholders. Repligen management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Repligen Return on Investment is quite stable at the moment as compared to the past year. The company's current value of Return on Investment is estimated at 9.06. Return on Average Assets is expected to rise to 6.53 this year, although the value of Return on Invested Capital will most likely fall to 0.11. Total Assets is expected to rise to about 2.5 B this year. Current Assets is expected to rise to about 1 B this year
The company currently holds 416.68 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Repligen has a current ratio of 2.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Repligen until it has trouble settling it off, either with new capital or with free cash flow. So, Repligen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Repligen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Repligen to invest in growth at high rates of return. When we think about Repligen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

CEO Since

Mitsuomi KoizumiJapan Tobacco ADR
2012
Howard LorberVector Group
2006
Debra CrewBritish American Tobacco
2017
Lars DahlgrenSwedish Match Ab
2008
Nicandro DuranteBritish American Tobacco
2011
Masamichi TerabatakeJapan Tobacco
2018
Mitsuomi KoizumiJapan Tobacco
2012
Guy MeldrumBritish American Tobacco
2020
Ronald BernsteinVector Group
2020
Masamichi TerabatakeJapan Tobacco ADR
2018
Ricardo OberlanderBritish American Tobacco
2018
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people. Repligen (RGEN) is traded on NASDAQ Exchange in USA and employs 1,852 people.

Repligen Leadership Team

Elected by the shareholders, the Repligen's board of directors comprises two types of representatives: Repligen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repligen. The board's role is to monitor Repligen's management team and ensure that shareholders' interests are well served. Repligen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repligen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Ryan, Independent Director
Christine Gebski, VP Chromatography
Kimberly Cornwell, Global Counsel
James Bylund, Chief Officer
James Rusche, Sr. VP of RandD
Howard Benjamin, VP of Bus. Devel.
Stephen Tingley, VP Sales
Tony Hunt, COO, Treasurer
Jon Snodgres, Chief Officer
Rachel Goodrich, VP Marketing
Ralf Kuriyel, Senior Vice President - Research & Development
Alexander Rich, Independent Chairman Emeritus of the Board
Glenn Muir, Director
Alfred Goldberg, Independent Director
Sondra Newman, Global Relations
Karen Dawes, Independent Chairperson of the Board
Glenn Cooper, Independent Director
John Cox, Director
Nicolas Barthelemy, Director
Anthony Hunt, President CEO, Director
Michael Griffith, Independent Director
Craig Harrison, VP Analytics

Repligen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Repligen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Repligen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Repligen's short interest history, or implied volatility extrapolated from Repligen options trading.

Currently Active Assets on Macroaxis

Additionally, take a look at Your Equity Center. Note that the Repligen information on this page should be used as a complementary analysis to other Repligen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Repligen Stock analysis

When running Repligen price analysis, check to measure Repligen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repligen is operating at the current time. Most of Repligen's value examination focuses on studying past and present price action to predict the probability of Repligen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Repligen's price. Additionally, you may evaluate how the addition of Repligen to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Is Repligen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine Repligen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.